BB&T Corp raised its position in shares of Celgene Corporation (NASDAQ:CELG) by 21.2% during the second quarter, Holdings Channel reports. The fund owned 23,956 shares of the biopharmaceutical company’s stock after buying an additional 4,194 shares during the period. BB&T Corp’s holdings in Celgene Corporation were worth $3,111,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Pensionfund Sabic purchased a new stake in shares of Celgene Corporation during the first quarter worth $2,688,000. Pensionfund DSM Netherlands purchased a new stake in shares of Celgene Corporation during the first quarter worth $5,363,000. Park National Corp OH increased its stake in shares of Celgene Corporation by 22.3% in the first quarter. Park National Corp OH now owns 3,752 shares of the biopharmaceutical company’s stock worth $467,000 after buying an additional 684 shares in the last quarter. First Financial Bank N.A. Trust Division increased its stake in shares of Celgene Corporation by 26.0% in the first quarter. First Financial Bank N.A. Trust Division now owns 2,420 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 500 shares in the last quarter. Finally, Private Asset Management Inc. increased its stake in shares of Celgene Corporation by 3.2% in the first quarter. Private Asset Management Inc. now owns 1,832 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 57 shares in the last quarter. Institutional investors own 78.41% of the company’s stock.

Celgene Corporation (CELG) traded down 3.02% during midday trading on Thursday, hitting $131.47. The stock had a trading volume of 1,311,764 shares. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00. The company has a 50-day moving average price of $134.30 and a 200-day moving average price of $124.13. The stock has a market cap of $102.86 billion, a P/E ratio of 40.72 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter last year, the firm posted $1.44 EPS. The company’s revenue was up 18.7% compared to the same quarter last year. Equities analysts expect that Celgene Corporation will post $7.32 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “BB&T Corp Boosts Position in Celgene Corporation (NASDAQ:CELG)” was reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/10/bbt-corp-boosts-position-in-celgene-corporation-nasdaqcelg.html.

CELG has been the topic of a number of analyst reports. Robert W. Baird reiterated an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a research report on Wednesday, April 19th. Barclays PLC reiterated an “equal weight” rating and issued a $125.00 price target (up from $120.00) on shares of Celgene Corporation in a research report on Sunday, April 23rd. Cann reiterated a “buy” rating on shares of Celgene Corporation in a research report on Thursday, April 27th. Cantor Fitzgerald set a $159.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, April 27th. Finally, BTIG Research reiterated a “buy” rating and issued a $138.00 price target on shares of Celgene Corporation in a research report on Monday, May 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have issued a buy rating to the stock. Celgene Corporation currently has a consensus rating of “Buy” and a consensus target price of $147.06.

In other Celgene Corporation news, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the sale, the director now directly owns 76,301 shares in the company, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 235,255 shares of company stock worth $31,377,042. Insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.